Remove Immune Response Remove Licensing Remove Life Science
article thumbnail

IXCHIQ Chikungunya Vaccine Trial Shows Sustained Immune Response in Adolescents

XTalks

IXCHIQ is the only licensed chikungunya vaccine in the US for adults aged 18 and older at increased risk of exposure to the virus. The study included 754 adolescents, comparing immune responses and safety profiles between vaccine and placebo groups. Following the announcement, Valnevas stock rose by 1.4%.

article thumbnail

Itolizumab Shows Positive Phase III Results in First-Line Treatment of Acute GVHD

XTalks

About aGVHD aGVHD is a life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It occurs when immune cells from the donor perceive the host tissues as foreign and subsequently initiate an immune response against them.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CanSinoBIO developed a highly effective COVID vaccine with an inhalant version

pharmaphorum

It then elicits an immune response against that spike protein. You have a response with immunoglobulins type G (antibodies) and robust cellular response with both CD4 and CD8 T-cells being activated,” Morgon states. We get a higher immune response with the inhaled compared to the injectable,” Morgon relays.

Vaccine 138
article thumbnail

BioNTech Partners with Matinas BioPharma to Develop New Delivery Technology for mRNA Vaccines

XTalks

In a joint news release , Matinas and BioNTech said they’ve also started discussions on a license agreement for Matinas’ LNC platform. Accomplishing strong immune responses with low doses is crucial in the development of well-tolerated and highly effective vaccines.

Vaccine 105
article thumbnail

Kaiser Permanente Joins Late-Stage Trial for Pfizer and BioNTech’s Lead COVID-19 Vaccine Candidate

XTalks

In a press statement , Kaiser Permanente outlined that in this phase of the trial, data will be collected about the safety, immune response and efficacy of the vaccine candidate as required for regulatory review.

Vaccine 89
article thumbnail

CMV Vaccine Trials: Moderna’s CMV mRNA Vaccine Enters Phase III

XTalks

The study compared the immune responses evoked by Moderna’s mRNA vaccine to those generated by a previous vaccine candidate, namely, the MF59-adjuvanted glycoprotein B (gB) proten subunit vaccine (gB/MF59) developed by Sanofi. After more than 50 years of research, we are closer than ever to having a licensed CMV vaccine,” Permar said.

Vaccine 59
article thumbnail

GSK’s Maria Reyes Boceta-Muñoz Talks Vaccine Development in a Post-Pandemic World

XTalks

Investigation of the possibility of VAED is crucial during clinical trials for decision-making on vaccine licensing by regulatory agencies. Finally, addressing the time-consuming and costly transition from non-clinical to clinical development due to difficulties in predicting human immune responses is another issue.

Vaccine 96